Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$14.65 USD
-0.50 (-3.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSTL 14.65 -0.50(-3.30%)
Will CSTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
New Strong Sell Stocks for August 1st
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
GSK (GSK) Q1 Earnings Surpass Estimates
Other News for CSTL
Examining the Future: Castle Biosciences's Earnings Outlook
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference | CSTL ...
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the ...
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
Castle Biosciences (CSTL) Gains FDA Breakthrough Device Status for Melanoma Test | CSTL Stock News